title: Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome.
abstract: OBJECTIVE
  To examine the clinical and functional outcome of adults with juvenile idiopathic arthritis (JIA) using the recent World Health Organization/International League Against Rheumatism (ILAR) classification.
  
  
  METHODS
  Two hundred and fifty-nine adults with long-standing JIA (average disease duration 28.3 yr) were eligible for the study; 246 (95%) attended for an interview, clinical examination and notes review and 231 (89.2%) returned a comprehensive functional and psychosocial self-assessment questionnaire.
  
  
  RESULTS
  Of all patients, 43.3% had active arthritis clinically and 54.4% on laboratory measures (C-reactive protein). Clinical inflammation was less common in systemic-onset JIA. The percentage of all patients with severe disability (Health Assessment Questionnaire score >1.5) was 42.9. Uveitis occurred frequently in the oligoarticular-onset and enthesitis-related subsets. Over 30% of the extended oligoarticular group with uveitis developed glaucoma compared with none of the enthesitis group.
  
  
  CONCLUSIONS
  Adults with JIA often have significant levels of disability, often related to continuing active disease over prolonged periods. There is a clear need for good transition from paediatric to high-quality adult rheumatology care.
authors.affiliation: Oxford Regional Paediatric Rheumatology Unit, Wexham Park Hospital, Slough SL2 4HL, UK.
authors.forename: J C
authors.initials: JC
authors.lastname: Packham
authors.forename: M A
authors.initials: MA
authors.lastname: Hall
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000368:Aged; D000686:Amyloidosis / Q000150:complications; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000974:Antibodies, Antinuclear / Q000032:analysis; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001171:Arthritis, Juvenile / Q000150:complications / Q000276:immunology; D001799:Blood Sedimentation; D002097:C-Reactive Protein / Q000032:analysis; D002908:Chronic Disease; D004185:Disability Evaluation; D005260:Female; D005500:Follow-Up Studies; D006130:Growth Disorders / Q000150:complications; D006304:Health Status; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood; D007596:Joints / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D014605:Uveitis / Q000150:complications
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000974:Antibodies, Antinuclear; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D002097:C-Reactive Protein